Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepboundnews2026-03-12T10:53:16+00:00March 12th, 2026|Endpoints News|
Novo Holdings’ assets fell by a third in 2025 as Novo Nordisk’s value sanknews2026-03-12T07:00:56+00:00March 12th, 2026|Endpoints News|
Evotec plans up to 800 job cuts, four site closuresnews2026-03-11T19:44:46+00:00March 11th, 2026|Endpoints News|
FDA merges adverse event trackers into one databasenews2026-03-11T19:44:22+00:00March 11th, 2026|Endpoints News|
Lilly plots GLP-1 pill production boost in China, $500M pledge to South Koreanews2026-03-11T15:15:38+00:00March 11th, 2026|Endpoints News|
UCB says Bimzelx tops Skyrizi in trial; Xenon, Dianthus set share salesnews2026-03-11T14:52:55+00:00March 11th, 2026|Endpoints News|
Eli Lilly CEO David Ricks seeks ‘exit velocity’ for pharma’s futurenews2026-03-11T14:37:56+00:00March 11th, 2026|Endpoints News|
RA Capital, Forbion and Canaan appear to back Harbour’s CTLA-4 partner Solsticenews2026-03-11T11:00:40+00:00March 11th, 2026|Endpoints News|
Study suggests long non-coding RNA has potential as new class of genetic medicinenews2026-03-10T20:02:18+00:00March 10th, 2026|Endpoints News|
Lundbeck CEO talks drug pricing, protecting biotech and European needsnews2026-03-10T18:28:19+00:00March 10th, 2026|Endpoints News|
